Statins pose no ALS risk, US FDA says
This article was originally published in Scrip
Executive Summary
The US FDAmay pursue additional epidemiologic studies to examine the incidence and clinical course of amyotrophic lateral sclerosis (ALS), or Lou Gehrig's disease, in patients taking statins, despite not seeing any increased risk with the cholesterol drugs in a retrospective review of clinical trials.